---
title: "Weekly Recap | Medtronic -3.41%, most brokers rate it buy"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/298792849.md"
description: "Medtronic fell 3.41% this week to close at $90.96. The S&P 500 lost 0.8%, so the stock underperformed the benchmark by about 2.61 percentage points. The holiday-shortened week had just four sessions. Shares opened Tuesday at $93.25 but failed to hold gains, drifted lower on Wednesday, hit an intraday low of $90.58 on Thursday, and ended Friday near the low of the week. The weekly range was 3.36%, and average daily volume of 6.6m shares ran about 12.6% below the 60-day median."
datetime: "2026-09-12T06:17:49.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/298792849.md)
  - [en](https://longbridge.com/en/news/298792849.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/298792849.md)
generator: "portal-rs"
---

# Weekly Recap | Medtronic -3.41%, most brokers rate it buy

## The Week

Medtronic fell 3.41% this week to close at $90.96. The S&P 500 lost 0.8%, so the stock underperformed the benchmark by about 2.61 percentage points. The holiday-shortened week had just four sessions. Shares opened Tuesday at $93.25 but failed to hold gains, drifted lower on Wednesday, hit an intraday low of $90.58 on Thursday, and ended Friday near the low of the week. The weekly range was 3.36%, and average daily volume of 6.6m shares ran about 12.6% below the 60-day median.

## Key Events

The week carried a fairly dense company news flow. Medtronic released its Q1 FY2027 earnings call transcript and stepped up its surgical robotics push. On 8 September, Orchestra BioMed highlighted over $500m in annual royalty potential from the AVIM pacemaker therapy partnered with Medtronic. On 9 September, Medtronic presented at the Wells Fargo conference, focusing on growth in AI, robotics and ablation. Earlier in the week the stock outperformed some peers on a down day, and some market commentary argued Wall Street is not paying enough attention to the high-yield healthcare name. On 11 September, analyst Brandon Vazquez reaffirmed a buy rating, citing a strong FY2027 outlook and an attractive risk-reward profile.

## Analyst Ratings

A total of 30 institutions cover Medtronic. Of these, 20 rate it buy or overweight, 9 rate it hold, and 1 has no opinion; none rate it underweight or sell. The consensus rating is buy, with a consensus target price of $104.76, about 15.17% above the latest close of $90.96. Targets range from $85 to $121, showing meaningful dispersion. Medtronic ranks 4th by rating among 142 stocks in the medical device industry.

## The Week Ahead

Next week’s macro calendar is heavy on US retail data. The New York Fed manufacturing index lands on 15 September, with a prior reading of 20.6 and a forecast of 14.75. On 16 September, retail sales, retail sales ex-autos, import prices, the NAHB housing market index and EIA crude inventories are all due. Retail sales have been choppy month to month. A soft print could weigh further on risk appetite for medical device names like Medtronic.

## In Short

Medtronic shares moved lower this week even as the analyst backdrop leaned positive. The stock trades around 22.24x earnings with a dividend yield of 3.13%, mid-range for the medical device sector. On the latest trading day, large-lot money was a net buyer while small and medium orders tilted the other way, a split worth watching. Retail data next week will set the tone for broader risk appetite, while the surgical robotics and AI narrative still needs a clearer catalyst to narrow the gap between ratings and price action.

*This article is generated by LongbridgeAI from market data, for information only and not investment advice.*

### Related Stocks

- [MDT.US](https://longbridge.com/en/quote/MDT.US.md)

## Related News & Research

- [What Is Medtronic (MDT) Asking Of Hypertension Care With Its FDA Label Update?](https://longbridge.com/en/news/304657327.md)
- [Cornerstone Robotics Limited Receives Approximately $700M Strategic Investment](https://longbridge.com/en/news/304858134.md)
- [TCT26: Medtronic Symplicity blood pressure procedure shows significant blood pressure drops in SPYRAL AFFIRM real-world study | MDT Stock News](https://longbridge.com/en/news/304159439.md)
- [Is the Stock Market Going to Crash? Warren Buffett's Warning Is Hard to Ignore.](https://longbridge.com/en/news/305154637.md)
- [US SEC seeks to close Musk, Tesla settlement fund](https://longbridge.com/en/news/305073867.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**